In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The New Generation Of Investor: Creating Value From Diamonds In The Rough

Executive Summary

Debbie Dumont, co-founder of Bioqube Ventures, and one of In Vivo’s Rising Leaders, talks about the company’s investment model, Europe’s translational challenges, and aligning  passion and purpose to find ultimate fulfilment.

You may also be interested in...



Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition

AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.

Bioqube Takes The Reins At J&J Innovation's JLINX

The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.

Flight Of The Navigator: Bluebird bio's Andrew Obenshain

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV146728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel